(NASDAQ: DARE) Dare Bioscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Dare Bioscience's revenue in 2025 is -$17,701.On average, 2 Wall Street analysts forecast DARE's revenue for 2025 to be $22,470,330, with the lowest DARE revenue forecast at $336,988, and the highest DARE revenue forecast at $44,617,152. On average, 1 Wall Street analysts forecast DARE's revenue for 2026 to be $567,487,034, with the lowest DARE revenue forecast at $567,487,034, and the highest DARE revenue forecast at $567,487,034.
In 2027, DARE is forecast to generate $1,316,947,345 in revenue, with the lowest revenue forecast at $1,316,947,345 and the highest revenue forecast at $1,316,947,345.